Rectal swab detection of ESBL, carbapenemases, and high-level cephalosporinase to predict C3G-resistant Enterobacteriaceae infections in ICU patients
Predictive Value of a Rectal Swab With Detection of Enterobacteria (ESBL-E), Carbapenemases, and High-level Cephalosporinase (HLC) on the Risk of Infections With C3G-resistant Enterobacteria in Intensive Care
This study tests whether a rectal swab that finds ESBL, carbapenemases, or high-level cephalosporinase can predict which adult ICU patients at Strasbourg are likely to get C3G-resistant Enterobacteriaceae infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07345923 on ClinicalTrials.gov |
What this trial studies
This is an observational cohort of adult medical and surgical ICU patients at Strasbourg University Hospitals who had rectal screening for ESBL/HLC/carbapenemase carriage between January 1, 2024 and January 1, 2025. Investigators will link colonization results from rectal swabs to subsequent clinical and microbiology records to identify infections with C3G-resistant Enterobacteriaceae. No experimental interventions are given; the study analyzes existing diagnostic and outcome data to estimate predictive value. Findings aim to quantify how well carriage detected by rectal swab forecasts later resistant infections in this ICU population.
Who should consider this trial
Good fit: Adult medical or surgical ICU patients at Strasbourg University Hospitals who underwent rectal screening for ESBL/HLC/carbapenemase carriage between January 1, 2024 and January 1, 2025.
Not a fit: Patients who were not screened with a rectal swab, were treated outside the specified ICUs or time window, were under 18, or who carry organisms not covered by these markers are unlikely to benefit.
Why it matters
Potential benefit: If successful, the test could help identify ICU patients at high risk for resistant enterobacterial infections so clinicians can tailor empiric antibiotics and infection-control measures.
How similar studies have performed: Previous observational studies have shown that rectal carriage of ESBL- and carbapenemase-producing Enterobacteriaceae often predicts subsequent infection, though predictive accuracy varies by setting and the role of high-level cephalosporinase markers is less well established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (≥ 18 years old) * Who have been in medical or surgical intensive care at Strasbourg University Hospitals (between January 1, 2024, and January 1, 2025) * Who have undergone rectal screening for carriage of ESBL/HLC/carbapenemase-producing Enterobacteriaceae Exclusion Criteria: * Refusal to participate in the study
Where this trial is running
Strasbourg
- Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: baptiste Hoellinger, MD
- Email: baptiste.hoellinger@chru-strasbourg.fr
- Phone: 33 3 69 55 05 45
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.